Pharma · Private company
Incyte Biosciences International Sàrl
Track this companyFree. Adds Incyte Biosciences International Sàrl to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- EpacadostatPhase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- INCAGN01876Phase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- INCAGN01876Phase 2 · Metastatic Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- INCAGN01949Phase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- INCAGN02385Phase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- INCAGN02390Phase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- retifanlimabPhase 2 · Metastatic Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RetifanlimabPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- INCAGN02385Phase 1 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPHASE2 · WITHDRAWN · started Mar 1, 2023ClinicalTrials.gov NCT05359692 · fetched Nov 12, 2026
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckPHASE2 · COMPLETED · started Nov 14, 2022ClinicalTrials.gov NCT05287113 · fetched Nov 12, 2026
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesPHASE1 · COMPLETED · started Jun 18, 2018ClinicalTrials.gov NCT03538028 · fetched Nov 12, 2026
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesPHASE1_PHASE2 · TERMINATED · started Nov 21, 2017ClinicalTrials.gov NCT03277352 · fetched Nov 12, 2026
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesPHASE1_PHASE2 · COMPLETED · started Oct 9, 2017ClinicalTrials.gov NCT03241173 · fetched Nov 12, 2026
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesPHASE1_PHASE2 · COMPLETED · started Apr 25, 2017ClinicalTrials.gov NCT03126110 · fetched Nov 12, 2026
- A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsPHASE1_PHASE2 · COMPLETED · started Oct 31, 2016ClinicalTrials.gov NCT02923349 · fetched Nov 12, 2026
- A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid TumorsPHASE1_PHASE2 · COMPLETED · started Jun 20, 2016ClinicalTrials.gov NCT02697591 · fetched Nov 12, 2026